NASDAQ:INGNInogen Stock Price, Forecast & News

Inogen's stock was trading at $40.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INGN shares have decreased by 6.2% and is now trading at $38.11. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Inogen.

Inogen is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Inogen.

Inogen Inc (NASDAQ:INGN) posted its quarterly earnings data on Tuesday, May, 5th. The medical technology company reported ($0.07) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.04. The medical technology company had revenue of $88.49 million for the quarter, compared to analyst estimates of $82.33 million. Inogen had a return on equity of 4.93% and a net margin of 3.90%. The company's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period last year, the business earned $0.24 earnings per share. View Inogen's earnings history.

6 equities research analysts have issued 12 month price targets for Inogen's shares. Their forecasts range from $45.00 to $80.00. On average, they anticipate Inogen's stock price to reach $60.80 in the next twelve months. This suggests a possible upside of 59.5% from the stock's current price. View analysts' price targets for Inogen.

News articles about INGN stock have trended negative recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Inogen earned a news impact score of -2.7 on InfoTrie's scale. They also gave news coverage about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutInogen.

Inogen saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,350,000 shares, an increase of 16.3% from the April 30th total of 2,020,000 shares. Based on an average trading volume of 464,400 shares, the days-to-cover ratio is presently 5.1 days. Approximately 12.9% of the company's stock are short sold. View Inogen's Current Options Chain.

Some companies that are related to Inogen include Wound Management Technologies (WNDM), Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Sientra (SIEN), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Rewalk Robotics (RWLK), Histogenics (HSGX), Precision Therapeutics (POAI), Ocugen (OCGN) and Bionik Laboratories (BNKL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), First Solar (FSLR), Netflix (NFLX), Intel (INTC) and Advanced Micro Devices (AMD).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Brown Capital Management LLC (16.85%), BlackRock Inc. (13.44%), Fred Alger Management LLC (6.82%), State Street Corp (3.10%), New York State Common Retirement Fund (2.21%) and Two Sigma Advisers LP (1.36%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View institutional ownership trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Federated Hermes Inc., BlackRock Inc., Summit Creek Advisors LLC, Canada Pension Plan Investment Board, Healthcare of Ontario Pension Plan Trust Fund, Two Sigma Advisers LP, and Squarepoint Ops LLC. View insider buying and selling activity for Inogen.

INGN stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, JPMorgan Chase & Co., Matarin Capital Management LLC, Morgan Stanley, Morgan Stanley, Avalon Investment & Advisory, Needham Investment Management LLC, and RK Capital Management LLC. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland. View insider buying and selling activity for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $38.11.

Inogen has a market capitalization of $840.25 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe.

The official website for Inogen is www.inogen.com.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]